<!DOCTYPE html>
<html lang="en">
  <head>
            
   

<meta charset="UTF-8" />
<meta name="viewport" content="width=device-width, initial-scale=1.0" />
<meta http-equiv="X-UA-Compatible" content="ie=edge" />

<link rel="shortcut icon" href="/wiki/assets/favicon.ico" type="image/x-icon" />

<title>Diabetes Second Line • Kang Rui Xiang's Notes</title>

<meta name="description" content="This is my wiki page" />

<meta property="og:title" content="Diabetes Second Line • Kang Rui Xiang's Notes" />
<meta property="og:type" content="article" />
<meta property="og:url" content="https://kangruixiang.github.io/wiki//notes/diabetes second line/" />
<meta property="og:image" content="/assets/avatar.png" />
<meta property="og:description" content="This is my wiki page" />

<link rel="canonical" href="https://kangruixiang.github.io/wiki//notes/diabetes second line/" />

<link rel="stylesheet" href="/wiki/style.css" />

  </head>
  <body>
    <div
      class="fixed top-0 w-screen px-4 py-4 md:px-10 bg-slate-200 bg-opacity-90"
    >
    <div class="flex items-center justify-between max-w-6xl mx-auto">
      <a href="/wiki/" title="Home">
        <img src="/wiki/assets/avatar.png" class="w-10 h-10 " />
      </a>

      <nav class="flex space-x-2 uppercase">
        <a href="/wiki/" class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Home</a
        >
        <a
          href="/wiki/notes/Step 1"
          class="p-4 rounded hover:bg-slate-600 hover:text-slate-200"
          >Step 1</a
          >
      </nav>
    </div>
    </div>
    <div class="mx-auto">

    <div class="flex items-center justify-center max-w-full px-6 mt-32 mb-32">
      <div  class="prose"><h1>diabetes second line</h1>
<ul>
<li>related: <a href="/wiki/notes/Endocrine/">Endocrine</a></li>
</ul>
<!-- diabetes when to initiate second agent-->
<ul>
<li>advance to dual therapy when A1C &gt; 9% after 3 months of metformin</li>
</ul>
<p>Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is an appropriate adjunctive agent with metformin in this patient as it will improve glycemic control and contribute to desired weight loss. There are potential concerns for development of pancreatitis and medullary thyroid carcinoma with GLP-1 receptor agonists. The patient does not have a personal or family history of these abnormalities to preclude use of liraglutide.</p>
<p>Empagliflozin, a sodium-glucose transporter-2 (SGLT2) inhibitor, may be added to metformin when the hemoglobin A1c remains above goal. SGLT2 inhibitor use improves glycemic control and induces weight loss, but it also increases the risk of genital mycotic infections. Empagliflozin should not be used in this patient because it may exacerbate her frequent vulvovaginal candidiasis infections.</p>
<p>Glipizide, a sulfonylurea, may also be added to metformin when the hemoglobin A1c remains above goal. Glipizide will improve glycemic control, but it is associated with weight gain that is not in concordance with the patient's desire for continued weight loss.</p>
<p>Basal insulin coverage can be provided with one to two daily injections of insulin detemir, glargine, or neutral protamine Hagedorn (NPH) insulin. Basal insulin may be added to metformin when the hemoglobin A1c level remains above goal. Basal insulin will improve glycemic control, but it is associated with weight gain that is not in concordance with the patient's desire for continued weight loss.</p>
</div>
      
    </div>

    <div class="max-w-4xl mx-auto prose">
                  <hr />
<p>Backlinks</p>


<ul>
  
  <li>
    <div class="">
      <a href="/wiki//notes/Endocrine/" class="peer">Endocrine</a>
      <div
        role="none"
        class="absolute hidden p-4 overflow-hidden prose-sm prose border rounded-md shadow-md w-fit max-h-80 peer-hover:block bg-stone-100 prose-headings:hidden prose-hr:hidden"
      >
        <h1>Endocrine</h1>
<ul>
<li>related: <a href="/wiki/notes/Medicine/">Medicine</a></li>
</ul>
<h2>Pituitary</h2>
<ul>
<li><a href="/wiki/notes/pituitary%20adenoma/">pituitary adenoma</a></li>
<li><a href="/wiki/notes/pituitary%20apoplexy/">pituitary apoplexy</a></li>
<li><a href="/wiki/notes/MEN/">MEN</a></li>
<li><a href="/wiki/notes/hyperprolactinemia/">hyperprolactinemia</a></li>
</ul>
<h2>Thyroid and Parathyroid</h2>
<ul>
<li><a href="/wiki/notes/hypothyroidism/">hypothyroidism</a></li>
<li><a href="/wiki/notes/hyperthyroidism/">hyperthyroidism</a></li>
<li><a href="/wiki/notes/subclinical%20hypothyroidism/">subclinical hypothyroidism</a></li>
<li><a href="/wiki/notes/thyroid%20nodules/">thyroid nodules</a></li>
<li><a href="/wiki/notes/Thyroid%20Dysfunction/">Thyroid Dysfunction</a></li>
<li><a href="/wiki/notes/thyroid%20cancer/">thyroid cancer</a></li>
<li><a href="/wiki/notes/Parathyroid/">Parathyroid</a></li>
<li><a href="/wiki/notes/vitamin%20D%20deficiency/">vitamin D deficiency</a></li>
<li><a href="/wiki/notes/myxedema%20coma/">myxedema coma</a></li>
<li><a href="/wiki/notes/euthyroid%20sick%20syndrome/">euthyroid sick syndrome</a></li>
<li><a href="/wiki/notes/methimazole/">methimazole</a></li>
</ul>
<h2>Adrenal</h2>
<ul>
<li><a href="/wiki/notes/adrenal%20insufficiency/">adrenal insufficiency</a></li>
<li>[[primary adr</li>
</ul>

      </div>
    </div>
  </li>
  
</ul>


</div>

    <footer>
      <div class="max-w-4xl mb-10 text-sm text-center mt-96 ">
        By Kang Rui Xiang
      </div>
      </div>
    </footer>
  </body>
</html>
